2026 IMS | IASO Bio Presented FUCASO China Real-World Data

Data ReadoutpositiveFUCASOPositive

AI Analysis

Summary

IASO Bio presented real-world data from a China study of 281 heavily pretreated patients with relapsed/refractory plasma cell neoplasms showing FUCASO achieved 95.9% objective response rate and 94.1% MRD negativity rate.

Clinical Trial Data

Primary Endpoint

Met

Patients

281

Outcome Details

95.9% objective response rate, 77.2% CR/sCR rate, 94.1% MRD negativity rate in 281 heavily pretreated patients

Importance:6/10

Sentiment:

0.80

real-world dataChinaplasma cell neoplasmsrelapsed/refractoryhigh-risk patientsMRD negativity

Related Companies

$ALMDT.PA $CHHE $WHEN

Read the original article

Published by PR Newswire Clinical Trials on September 27, 2026 3:16 AM

Read Original